MANA Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

MANA Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,533	Closed	-$576K	–	196
2017 Q4	$576K	Buy	+4,533	New	+$570K	0.25%	151

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

MANA Advisors's ALNY Position: Q1 2018 in Review

MANA Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2018, closing a stake of 4,533 shares — an estimated $576K sold.

MANA Advisors first reported a position in ALNY in Q4 2017 and held it in 1 quarter. The position peaked at $576K in Q4 2017. 292 funds tracked by Wall St. Rank hold ALNY as of Q1 2018.

MANA Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
MANA Advisors sold 4,533 Alnylam Pharmaceuticals shares in Q1 2018, an estimated $576K.
MANA Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2017 and held it in 1 quarter.
MANA Advisors's Alnylam Pharmaceuticals position peaked at $576K in Q4 2017.
292 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2018.

Based on MANA Advisors's 13F filing for Q1 2018, filed 15 May 2018.